Randomized phase II study of cetuximab versus irinotecan and cetuximab in patients with chemo-refractory KRAS codon G13D metastatic colorectal cancer (G13D-study)

Masato Nakamura1 · Toru Aoyama2 · Keiichiro Ishibashi3 · Akihito Tsuji4 · Yasutaka Takinishi5 · Yoshiaki Shindo6 · Junichi Sakamoto7 · Koji Oba8 · Hideyuki Mishima9

Received: 23 August 2016 / Accepted: 13 November 2016 / Published online: 22 November 2016
© The Author(s) 2016. This article is published with open access at Springerlink.com

Abstract

Purpose This study investigated the efficacy and safety of cetuximab-based treatment in patients with chemotherapy-resistant refractory mCRC with KRAS G13D mutation.

Patients and methods An assessment of the efficacy and safety of cetuximab-based treatment was performed in an observation-enriched randomized controlled study comparing the cetuximab alone group (Cet group) and the combination of cetuximab and irinotecan group (CetI group) for KRAS G13D-mutated mCRC in Japan. In this study, the patients received a biweekly (500 mg/m² on day 1) or weekly (250 mg/m²) intravenous infusion of cetuximab in Cet group, or a biweekly (500 mg/m² on day 1) or weekly (250 mg/m²) intravenous infusion of cetuximab followed by irinotecan (150 mg/m²) in CetI group. Propensity score adjustment was used to achieve balance in the observational arm.

Results Data from a total of 29 patients (10 in Cet group, 19 in CetI group) were analyzed. Crude median progression-free survival time was 2.9 months in the Cet group and 2.5 months in the CetI group. Crude disease control rates were 55.6% in the Cet group and 47.4% in the CetI group. After a median follow-up of 43 months, the crude median overall survival was 8.0 months in the Cet group and 7.6 months in the CetI group. Cetuximab-based treatment did not markedly increase any characteristic toxicity and was generally well tolerated. Propensity score analyses adjusted for performance status and number of metastases showed comparable results with the crude results.

Conclusion Cetuximab-based treatment seemed to benefit patients with chemotherapy-resistant, refractory KRAS G13D-mutated mCRC. Our results might support the administration of cetuximab-based treatment for KRAS-mutant mCRC and would be able to provide treatment flexibility in this setting.

Keywords Cetuximab · KRAS G13D · Colorectal cancer

Introduction

Colorectal cancer (CRC) is the third-most common malignant disease and one of the most frequent causes of cancer-related death worldwide [1]. Complete resection is essential for the cure of CRC. However, metastatic CRC (mCRC) cannot be cured by surgical resection alone, and the prognosis of such patients is poor [2, 3].
Significant advances in the treatment of mCRC have been achieved by the addition of molecular targeting agents to standard mCRC chemotherapy. Cetuximab is the first chimeric human-mouse monoclonal antibody of immunoglobulin G1 (IgG1) subclass directed against epidermal growth factor receptor (EGFR) [4, 5]. Cetuximab has been shown to be effective in the treatment of mCRC when administered either as monootherapy or in combination with other chemotherapeutic agents [6, 7]. However, retrospective studies and prospective randomized phase III studies of mCRC indicated that mCRC patients with KRAS codon 12 or 13 mutations do not benefit from cetuximab [8]. The health authorities in Europe, the US, and Japan have therefore recommended compulsory KRAS mutation testing [9, 10]. In this respect, patients with KRAS codon 12 or KRAS codon 13 mutated tumors cannot receive cetuximab in Europe or the US. Although standard cytotoxic chemotherapy and/or bevacizumab are typically used for mCRC treatment, no valid and effective treatment for refractory mCRC patients with mutations of KRAS either in codon 12 or 13 has yet been established. In this regard, the development of a treatment for such cases is imperative to improve the outcome of these mCRC patients.

Recently, De Roock et al. [11] investigated the association between KRAS mutation status (G13D vs. other KRAS mutations) and response and survival in a pooled data set of 579 patients with chemotherapy-refractory CRC treated with cetuximab. They found that administration of cetuximab was associated with longer overall and progression-free survival among patients with chemotherapy-refractory CRC with G13D-mutated tumors than with other KRAS-mutated tumors. Furthermore, in vitro experiments revealed that cancer cells with KRAS codon 13 mutation had a weaker level of resistance to apoptosis than those with KRAS codon 12 mutations [12]. However, these findings were obtained from retrospective studies or subgroup analyses. Therefore, a prospective validation study was warranted to confirm those findings. On the other hand, the randomized phase II BOND study (Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer) demonstrated significant improvement in response rate and progression-free survival with the addition of irinotecan to cetuximab in the refractory setting in molecularly unselected patients whose disease had progressed on irinotecan. According to the Bond study, we estimated synergy effects between cetuximab and irinotecan or response to irinotecan rechallenge despite prior progression on that drug.

To optimize mCRC patients’ treatment options, this randomized phase II study was designed with the aim of evaluating the efficacy of cetuximab and the additional effect of irinotecan on cetuximab-based therapy in mCRC patients with a mutation in KRAS codon G13D.

Materials and methods

Study design

This was a multicenter, open-label, prospective phase II study investigating the efficacy and safety of cetuximab and irinotecan plus cetuximab in patients with chemorefractory mCRC with mutation at KRAS codon G13D. The study data and informed consent were obtained in accordance with the Declaration of Helsinki, and the study protocol was approved by the Ethics Review Board of each institution.

The study design was an observation-enriched randomized controlled design. During the informed consent process, each patient selected whether they wanted to join the observation arm or randomization arm if they accepted the trial participation. If patients chose the observation arm, they picked the study treatment (irinotecan alone or irinotecan plus cetuximab) they wanted to be in. Otherwise, they were centrally randomized to irinotecan alone or irinotecan plus cetuximab with a minimization technique (stratification factors were performance status and institution).

Patients

Patients were eligible if they were ≥20 years of age and had histologically confirmed mCRC; already received first-line chemotherapy for mCRC; a known G13D KRAS mutation status; measurable disease as assessed according to Response Evaluation Criteria in Solid Tumors (RECIST); an Eastern Cooperative Oncology Group performance status ≤1; and adequate hepatic, renal, and bone marrow function [white blood cell (WBC) count ≥3000 and ≤12,000/mm³, neutrophil count ≥1500/mm³, platelet count ≥100,000/mm³, GOT and GPT ≤100 U/l, total bilirubin <1.5 mg/dl, creatinine <1.5 mg/dl, and normal ECG]. Patients were ineligible if they had a history of previous exposure to EGFR-targeted therapy and/or uncontrolled severe organ/metabolic dysfunction.

Study treatment

The enrolled patients started protocol treatment within 14 days after registration: a biweekly intravenous (IV) infusion of cetuximab (500 mg/m² on day 1) or a weekly IV infusion of cetuximab (an initial intravenous infusion of 400 mg/m² with subsequent weekly doses of 250 mg/m²) (Cet group); a biweekly IV infusion of irinotecan (150 mg/m² on day 1) plus a biweekly IV infusion of cetuximab (500 mg/m² on day 1) or a weekly IV infusion of cetuximab...
(an initial intravenous infusion of 400 mg/m² with subsequent weekly doses of 250 mg/m²) (Cet group).

**KRAS and BRAF mutations**

DNA was extracted from formalin-fixed paraffin-embedded tumor tissues. Mutation of KRAS at codon 13 was detected by direct sequencing, as described previously [13, 14].

**Endpoints**

The primary endpoint was progression-free survival (PFS). The PFS of patients without disease progression before the end of the study was censored at the last on-study tumor assessment date at which the patient was considered to be progression-free. PFS was defined as the number of days between the enrollment and the first on-study assessment of disease progression (PD) or any cause of death.

The secondary endpoints were the disease control rate, overall survival (OS), and the safety of the combination therapy. The RECIST 1.1 criteria were applied subsequently to assess and confirm the overall response. A radiologic assessment was performed at baseline, every 8 weeks during the first 6 months of the study, and every 12 weeks thereafter until PD. The OS was defined as the number of days between the enrollment and any cause of death. Patients who did not die were censored at the last follow-up date. Adverse events were collected throughout the study period. All adverse events recorded were graded according to the Common Terminology Criteria for Adverse Events version 4.0.

**Statistical analyses**

For the crude analysis, we analyzed all patients who enrolled in the trial without statistical adjustments. All summary statistics on time-to-event variables were calculated according to the Kaplan–Meier methods. The 95% confidence intervals (CIs) for median time-to-event and the time-specific incidence rate were constructed using Greenwood’s formula and Brookmeyer and Crowley’s method, respectively. The Cox proportional hazard model was used to estimate the hazard ratio (HR) and its 95% CI between the Cet group and CetI group.

Propensity score was used to adjust the unbalance of prognostic factor between Cet group and CetI group in the observation arm to combine results of the randomization arm with the observation arm. Propensity score was estimated using the logistic regression model. The variable used for the logistic model was selected based on the standardized difference between two groups. Using the stabilized inverse propensity score as weight, we created the pseudo-population using the total patients of observation arm as the standard population. A stratified analysis was used to summarize the results from randomization arm and observation arm.

The sample size was determined only for the randomization group. Assuming an absolute difference in 6 month PFS rate of ≥26% between the C group and CI group, 15 patients for each group were needed to observe improved treatment with 95% probability. We planned to enroll patients in the observation arm until the target sample sizes in the randomization arm were achieved.

**Results**

**Patients’ characteristics**

From July 2012 to May 2015, 43 institutions collaborated with the G13D-study, and 33 patients were registered from 23 institutions. Four patients did not have KRAS G13D mutations. Accordingly, 29 patients were defined as eligible for this study. Figure 1 shows the CONSORT diagram. The intention-to-treat population consisted of 29 patients. A safety analysis was carried out on those 29 patients who received at least 1 dose of any component of the study treatment. The patients’ clinical characteristics at baseline are shown (Table 1). The median age of the patients was 69 years (range 37–83 years). In the first-line chemotherapy, 16 patients received bevacizumab and chemotherapy and 4 patients received irinotecan-based chemotherapy. Twelve patients (41.4%) had metastatic lesions in 1 organ, and 17 patients (58.6%) had metastatic lesions in more than 1 organ. As expected, hepatic metastases were the most common, with lesions detected in 17 patients (58.6%).

![Fig. 1 CONSORT diagram of the present study](image-url)
Efficacy

After a median follow-up of 43 months, the crude median PFS was 2.9 months (95% CI 0.7–4.3) in the Cet group and 2.5 months (95% CI 2.1–3.5) in the CetI group (Fig. 2), which was not statically different (HR = 0.69, 95% CI 0.30–1.59, p = 0.380). In addition, the crude median OS was 8.0 months (95% CI 1.9–14.1) in the Cet group and 7.6 months (95% CI 3.9–11.5) in the CetI group (Fig. 3), which was not statically different (HR = 0.87, 95% CI 0.39–1.95, p = 0.741). In addition, 6-month progression-free survival rates were 10% (95% CI 0.5–35.8%) in Cet group and 0% in CetI group. There was not significantly difference between two groups (p = 0.375).

The efficacy data are summarized in Table 2. The disease control rate (DCR) was 60% (95% CI 26–88) in the Cet group and 47% (95% CI 24–71) in the CetI group, which was not statically different (p = 0.800). The best

Table 1 Patient characteristics

| Characteristics | Total (n = 29) | Cetuximab alone (n = 10) | Cetuximab + CPT-11 (n = 19) |
|-----------------|---------------|--------------------------|-----------------------------|
| Gender          |               |                          |                             |
| Male            | 21 (72.4)     | 8 (80.0)                 | 13 (68.4)                   |
| Female          | 8 (27.6)      | 2 (22.2)                 | 6 (31.6)                    |
| Age (years)     |               |                          |                             |
| Median          | 69            | 69                       | 69                          |
| Range           | (37–83)       | (58–80)                  | (37–83)                     |
| ECOG performance status |       |                          |                             |
| 0               | 19 (65.5)     | 4 (40.0)                 | 15 (78.9)                   |
| 1               | 10 (34.5)     | 6 (60.0)                 | 4 (21.1)                    |
| Cancer location |               |                          |                             |
| Colon           | 16 (55.2)     | 7 (70.0)                 | 9 (47.4)                    |
| Rectum          | 13 (44.8)     | 3 (30.0)                 | 10 (52.6)                   |
| Primary site resection |       |                          |                             |
| No              | 19 (65.5)     | 6 (60.0)                 | 13 (68.4)                   |
| Yes             | 10 (34.5)     | 4 (40.0)                 | 6 (31.6)                    |
| Previous chemotherapy therapy line |       |                          |                             |
| 1st, 2nd line   | 25 (86.2)     | 8 (80.0)                 | 17 (89.5)                   |
| 3rd, 4th line   | 4 (13.8)      | 2 (20.0)                 | 2 (10.5)                    |
| No. of organs with metastases |     |                          |                             |
| 1               | 12 (41.4%)    | 4 (40.0)                 | 8 (42.1)                    |
| 2               | 9 (31.0%)     | 5 (50.0)                 | 4 (21.1)                    |
| ≥3              | 8 (27.6%)     | 1 (10.0)                 | 7 (36.8)                    |
| Metastases site |               |                          |                             |
| Liver           | 17            | 5 (50.0)                 | 12 (63.2)                   |
| Lung            | 16            | 7 (70.0)                 | 9 (47.4)                    |
| Lymph node      | 10            | 3 (30.0)                 | 7 (36.8)                    |

ECOG Eastern Cooperative Oncology Group
response is shown in Fig. 4. In addition, the DCR was 41% in the patients who had hepatic metastases (40% in the Cet group and 42% in the CetI group), 50% in the patients who had lung metastases (57% in the Cet group and 44% in the CetI group), and 50% in the patients who had lymphatic metastases (100% in the Cet group and 29% in the CetI group). There were no differences in the DCR by metastatic organ.

Efficacy results after adjustment using propensity score

In the observation arm, performance status and number of metastasis showed discrepancy based on the standardized difference between Cet group and CetI group. Thus, we estimated propensity score using performance status and number of metastasis as covariates. After adjustment using propensity score, the HR for PFS was 1.15 (95% CI 0.45–2.93) and there was no statistical difference between Cet and CetI group ($p = 0.765$). OS was also similar between two groups (HR = 1.03; 95% CI 0.44–2.41; $p = 0.950$).

Treatment compliance and safety

The median course of the study treatment was 2.6 months (range 2.2–3.4). The median course of the study treatment was 2.8 months (95% CI 0.7–4.7) in the Cet group and 2.5 months (95% CI 2.2–3.5) in the CetI group, which was not statically different. Patients achieving a relative dose intensity >80% for each drug are also shown.

Adverse events (AEs) of grade 3 or 4 occurring in at least 34.5% (10/29 patients) of the patients are summarized (Table 3). The most common grade 3 or 4 AEs were neutropenia, anorexia, and fatigue. Although the incidence of neutropenia was higher in the CetI group than in the Cet group, the rates of the other adverse events were similar between the two groups.

### Table 2 Efficacy data

| Parameter                  | All cases | Cetuximab alone ($n = 10$) | Cetuximab + CPT-11 ($n = 19$) | $p$ value |
|----------------------------|-----------|---------------------------|-------------------------------|-----------|
| Best overall response rate | Complete  | 0                         | 0                             | 0         |
|                            | Partial   | 0                         | 0                             | 0         |
|                            | Stable    | 15                        | 6                             | 9         |
|                            | Progressive | 12                      | 2                             | 10        |
|                            | Not assessable | 2                   | 2                             | 0         |
| Disease control rate       | 51.7%     | 60.0%                     | 47.4%                         | 0.800     |
| Median PFS (months)        | 2.6       | 2.9                       | 2.5                           | 0.380     |
| 95% CI                     | 2.1–3.3   | 0.7–4.3                   | 2.1–3.5                       |           |
| Progression events         | 29        | 10                        | 19                            |           |
| Censored                   | 0         | 0                         | 0                             |           |
| Median OS (months)         | 7.6       | 8.0                       | 7.6                           | 0.741     |
| 95% CI                     | 4.8–11.5  | 1.9–14.1                  | 3.9–11.5                      |           |
| Deaths                     | 26        | 10                        | 16                            |           |
| Censored                   | 3         | 0                         | 3                             |           |
| 1-year survival rate       | 27.9      | 30.0                      | 26.3                          |           |
| 95% CI                     | 9.9–41.1  | 7.1–57.8                  | 8.6–48.4                      |           |
| 2-year survival rate       | 8.0       | 10                        | 6.6                           |           |
| 95% CI                     | 1.4–22.3  | 0.6–35.8                  | 0.4–25.6                      |           |

*PFS* progression-free survival, *OS* overall survival, *CI* confidence interval
Discussion

This study was a prospective clinical trial to investigate the efficacy and safety of cetuximab-based treatment in patients with chemotherapy-resistant, refractory mCRC with KRAS G13D mutation. The present study showed that the treatment effects were similar to those in patients with KRAS wild-type tumors. Cetuximab-based treatment seemed to benefit patients with chemotherapy-resistant, refractory KRAS G13D-mutated mCRC, despite their mutation.

The median progression-free survival (PFS) was 2.9 months (95% CI 0.7–4.3) in the Cet group and 2.5 months (95% CI 2.1–3.5) in the CetI group in the present study. Similar PFS was observed, regardless of the treatment regimen. These results were similar to those of previous phase reports regarding the administration of cetuximab-based treatment in patients with refractory mCRC with KRAS G13D mutation. There have been two reports evaluating PFS in this setting. Bando et al. [15] retrospectively investigated the relationship between KRAS status and cetuximab efficacy among Japanese patients. In their study, 7 patients with refractory mCRC with KRAS G13D mutation were treated by a cetuximab + irinotecan regimen. No statistically significant differences in the PFS were observed between KRAS p.G13D-mutant and other mutant tumors. In addition, De Roock et al. [11] studied the association of KRAS G13D mutation with outcome after cetuximab treatment in a pooled data set of 579 patients with chemotherapy-refractory metastatic CRC treated with cetuximab with or without chemotherapy. They found that the patients with G13D-mutated tumors (n = 32) treated

![Waterfall plot of evaluable patients (n=27) for showing the largest decrease in the sum of the target lesions compared with baseline. 1 = stable disease in cetuximab monotherapy; 2 = stable disease in cetuximab plus irinotecan; 3 = progressive disease in cetuximab monotherapy; 4 = progressive disease in cetuximab plus irinotecan.](image)

Fig. 4 Best response of the present study

### Table 3 Relevant adverse events

| Adverse event          | All cases (Grade 3/4) | Cetuximab alone (Grade 3/4) | Cetuximab + CPT-11 (Grade 3/4) |
|------------------------|-----------------------|-----------------------------|---------------------------------|
|                        | Number of patients (%)| Number of patients (%)       | Number of patients (%)          |
| Hematological          |                       |                             |                                 |
| Leukopenia             | 1                     | 3.4                         | 0                               | 1                               | 5.3                            |
| Neutropenia            | 4                     | 13.8                        | 0                               | 4                               | 21.2                           |
| Anemia                 | 2                     | 6.8                         | 1                               | 10.0                            | 1                               | 5.3                            |
| Thrombocytopenia       | 0                     | 0                           | 0                               | 0                               | 0                               |
| No hematological       |                       |                             |                                 |                                 |                                 |
| Elevated ALP          | 2                     | 6.8                         | 1                               | 10.0                            | 1                               | 5.3                            |
| Elevated serum Bil    | 0                     | 0                           | 0                               | 0                               | 0                               |
| Elevated creatine     | 0                     | 0                           | 0                               | 0                               | 0                               |
| Stomatitis            | 0                     | 0                           | 0                               | 0                               | 0                               |
| Nausea/vomiting       | 1                     | 3.4                         | 0                               | 0                               | 1                               | 5.3                            |
| Diarrhea              | 1                     | 3.4                         | 0                               | 0                               | 1                               | 5.3                            |
| Rash                  | 0                     | 0                           | 0                               | 0                               | 0                               |
| Paronychia            | 0                     | 0                           | 0                               | 0                               | 0                               |
| Anorexia              | 4                     | 13.8                        | 2                               | 20.0                            | 2                               | 10.6                           |
| Fatigue               | 4                     | 13.8                        | 1                               | 10.0                            | 3                               | 15.9                           |
| Infusion related reaction | 0                  | 0                           | 0                               | 0                               | 0                               |
| Paresthesia           | 0                     | 0                           | 0                               | 0                               | 0                               |

*ALP* alkaline phosphatase, *Bil* bilirubin
with cetuximab had longer PFS than the patients with KRAS-mutated tumors in other locations (median 4.0 [95% CI 1.9–6.2] months vs. 1.9 [95% CI 1.8–2.8] months; adjusted HR = 0.51 [95% CI 0.32–0.81; p = 0.004]).

The PFS in the present study was slightly shorter than in previous reports, possibly due to differences in the study design, patient backgrounds, and details of treatment. In contrast, there was no significant difference in the PFS between the Cet group and the CetI group in the present study (HR = 0.69, 95% CI 0.30–1.59, p = 0.380). Similar results were observed in a recent phase II study; Segelov et al. [16] assessed cetuximab monotherapy and cetuximab plus irinotecan in patients with molecularly selected (G13D mutation) chemotherapy-refractory mCRC in a randomized phase II trial (ICECREAM study). They found that PFS in patients with KRAS G13D-mutated mCRC did not significantly differ between those treated with cetuximab monotherapy and those treated with combined cetuximab and irinotecan. Moreover, when comparing the present study results and ICECREAM trial results, the 6-month PFS of cetuximab monotherapy was similar although the number of patients was small. In the present study, we estimated synergy effects between cetuximab and irinotecan or response to irinotecan rechallenge despite prior progression on that drug in this setting. However, these effects were not observed in the present study. However, De Roock et al. reported conflicting findings that the median PFS was 1.8 (95% CI 1.7–11.0) months in the cetuximab monotherapy group (n = 10) versus 4.1 (95% CI 2.8–6.9) months in the cetuximab plus chemotherapy group (n = 22). These results might suggest a synergetic effect of cytotoxic agents and targeted agents or persistent chemotherapy sensitivity [16]. Future studies should focus on this issue.

The crude median OS was 8.0 months (95% CI 1.9–14.1) in the Cet group and 7.6 months (95% CI 3.9–11.5) in the CetI group, which was not statically different (HR = 0.87, 95% CI 0.39–1.95, p = 0.741). A similar HR was observed in the ICECREAM study (HR = 0.95 [95% CI 0.53–1.68]). Furthermore, the disease control rate (DCR) was 60% in the Cet group and 47.4% in the CetI group. The ICECREAM study showed that the response and stable disease rates were 0 and 58% for cetuximab monotherapy and 9 and 70% for cetuximab + irinotecan combination treatment, respectively [16].

Although 35% of patients experienced grade 3/4 AE in our study and hematological toxicities were slightly higher with combination therapy, the incidence of the worse toxicities in the combination was within the previously reported ranges. The cetuximab-based treatment was generally well tolerated, and there was no evidence suggesting that cetuximab-based treatment increased the frequency or severity of characteristic toxicities. The rate of grade 3/4 AE was 44–59% in the ICECREAM study [16].

One important limitation of the present study is the lack of pertaining to comparison with outcomes of previous standard regimen. The standard second-line treatment was cytotoxic chemotherapy, such as FORFOX or FORFIRI, with/without bevacizumab typically used for refractory mCRC patients with mutations of KRAS in codon 13 mutation. Moreover, the standard third-line treatment was cytotoxic chemotherapy for refractory mCRC patients with mutations of KRAS in codon 13 mutation. However, the patient’s background and treatment were quite different between the present study and the previous studies. Therefore, it is difficult to draw the definitive conclusions from the present study.

In conclusion, cetuximab-based treatment seemed to benefit patients with chemotherapy-resistant, refractory mCRC with KRAS G13D mutation. In addition, the present study showed that the cetuximab-based treatment was well tolerated and had a manageable safety profile for chemo-refractory mCRC with KRAS G13D mutation. Our results might support the administration of cetuximab-based treatment for mCRC with KRAS mutation in codon G13D despite their mutation, providing treatment flexibility in this setting.

Acknowledgements This study is supported, in part, by the nonprofit organization Epidemiological and Clinical Research Information Network (ECRIN).

Compliance with ethical standards

Conflict of interest The authors declare no conflicts of interest in association with the present study.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References

1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A (2015) Global cancer statistics, 2012. CA Cancer J Clin 65:87–108
2. Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ et al (2000) Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan study group. N Engl J Med 343:905–914
3. Köhne CH, van Cutsem E, Wils J, Bokemeyer C, El-Serafi M, Lutz MP et al (2005) Phase III study of weekly high-dose infusional fluorouracil plus folinic acid with or without irinotecan in patients with metastatic colorectal cancer: European Organisation for Research and Treatment of Cancer Gastrointestinal Group Study 40986. J Clin Oncol 23:4856–4865
4. Sunada H, Magun BE, Mendelsohn J, MacLeod CL (1986) Monoclonal antibody against epidermal growth factor receptor is internalized without stimulating receptor phosphorylation. Proc Natl Acad Sci USA 83:3825–3829
5. Li S, Schmitz KR, Jeffrey PD, Wiltzius JJ, Kussie P, Ferguson KM (2005) Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. Cancer Cell 7:301–311
6. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A et al (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351:337–345
7. Goldstein NS, Armin M (2001) Epidermal growth factor receptor immunohistochemical reactivity in patients with American Joint Committee on cancer stage IV colon adenocarcinoma: implications for a standardized scoring system. Cancer 92:1331–1346
8. Allegra CJ, Jessup JM, Somerfield MR, Hamilton EH, Hayes DF et al (2009) American society of clinical oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol 27:2091–2096
9. US Food and Drug Administration (2010) Cetuximab (Erbitux) and panitumumab (Vectibix). http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm172905.htm. Accessed 29 Mar 2010
10. European Medicines Agency (2007) Questions and answers on the marketing authorisation for Vectibix. http://www.emea.europa.eu/pdfs/human/opinion/40511307en.pdf. Accessed 29 Mar 2010
11. De Roock W, Jonker DJ, Di Nicolantonio F, Sartore-Bianchi A, Tu D, Siena S et al (2010) Association of KRAS p. G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA 304:1812–1820
12. Tejpar S, Celik I, Schlichting M, Sartorius U, Bokemeyer C, Van Cutsem E (2012) Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab. J Clin Oncol 30:3570–3577
13. Okayama N, Nishioa M, Hazama S, Sakai K, Suehiro Y, Maekawa M et al (2011) The importance of evaluation of DNA amplificability in KRAS mutation testing with dyeoxy sequencing using formalin-fixed and paraffin-embedded colorectal cancer tissues. Jpn J Clin Oncol 41:165–171
14. Iwamoto S, Hazama S, Kato T, Miyake Y, Fukunaga M, Matsuda C et al (2014) Multicenter phase II study of second-line cetuximab plus folinic acid/5-fluorouracil/irinotecan (FOLFIRI) in KRA wild-type metastatic colorectal cancer: the FLIER study. Anticancer Res 34:1967–1973
15. Bando H, Yoshino T, Yuki S, Shinozaki E, Nishina T, Kadowaki S et al (2012) Clinical outcome of Japanese metastatic colorectal cancer patients harbouring the KRAS p. G13D mutation treated with cetuximab + irinotecan. Jpn J Clin Oncol 42:1146–1151
16. Segelov E, Thavaneswaran S, Waring PM, Desai J, Robledo KP, Gbksvi VJ, et al (2016) Response to Cetuximab With or Without Irinotecan in Patients With Refractory Metastatic Colorectal Cancer Harboring the KRAS G13D Mutation: Australasian Gastro-Intestinal Trials Group ICECREAM Study. J Clin Oncol 34:2258–2264